128 related articles for article (PubMed ID: 476637)
1. Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells.
Wan CW; Mak TW
Cancer Res; 1979 Oct; 39(10):3981-5. PubMed ID: 476637
[TBL] [Abstract][Full Text] [Related]
2. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
[TBL] [Abstract][Full Text] [Related]
3. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M
Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412
[TBL] [Abstract][Full Text] [Related]
4. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
6. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.
Wong PP; Currie VE; Mackey RW; Krakoff IH; Tan CT; Burchenal JH; Young CW
Cancer Treat Rep; 1979 Aug; 63(8):1245-9. PubMed ID: 383291
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
Kreis W; Woodcock TM; Gordon CS; Krakoff IH
Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
[TBL] [Abstract][Full Text] [Related]
9. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
Vadi H; Drewinko B
Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232
[TBL] [Abstract][Full Text] [Related]
10. Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells.
Wan CW; Mak TW
Cancer Res; 1978 Sep; 38(9):2768-72. PubMed ID: 679182
[TBL] [Abstract][Full Text] [Related]
11. Decreased cytotoxicity of 1-beta-D-arabinofuranosylcytosine in 9L rat brain tumor cells pretreated with alpha-difluoromethylornithine in vitro.
Oredsson SM; Gray JW; Deen DF; Marton LJ
Cancer Res; 1983 Jun; 43(6):2541-4. PubMed ID: 6406046
[TBL] [Abstract][Full Text] [Related]
12. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells.
Riva C; Barra Y; Carcassonne Y; Cano JP; Rustum Y
Chemotherapy; 1992; 38(5):358-66. PubMed ID: 1286578
[TBL] [Abstract][Full Text] [Related]
13. The effect of 1-beta-D-arabinofuranosylcytosine on cell viability, DNA synthesis, and chromatid breakage in synchronized hamster fibrosarcoma cells.
Jones PA; Baker MS; Benedict WF
Cancer Res; 1976 Oct; 36(10):3789-97. PubMed ID: 986242
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
15. In vitro biochemical and cytotoxicity studies with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine in combination.
Momparler RL; Goodman J; Karon M
Cancer Res; 1975 Oct; 35(10):2853-7. PubMed ID: 50882
[TBL] [Abstract][Full Text] [Related]
16. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Grant S; Bhalla K; McCrady C
Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
[TBL] [Abstract][Full Text] [Related]
17. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
[TBL] [Abstract][Full Text] [Related]
18. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Greer SB
Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216
[TBL] [Abstract][Full Text] [Related]
19. Influence of tetrahydrouridine on the phosphorylation of 1-beta-D-arabinofuranosyl-cytosine (ara-C) by enzymes from solid tumors in vitro.
Furner RL; Mellett LB; Herren TC
J Pharmacol Exp Ther; 1975 Jul; 194(1):103-10. PubMed ID: 1057009
[TBL] [Abstract][Full Text] [Related]
20. Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate.
Liliemark JO; Plunkett W
Cancer Res; 1986 Mar; 46(3):1079-83. PubMed ID: 3484676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]